Search

Head of Scientific Publications

Hematologic diseases afflict millions of Europeans each year. The European Hematology Association (EHA), located in The Hague (Netherlands), is a non-profit professional association serving clinicians and researchers with an active interest in hematology in Europe and beyond.

Read more

EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies

In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)

Online registration is closed.

Read more

Stem Cells

Mission:

The goal of the SWG on Stem Cells is to bring together researchers, biologists and clinicians involved in stem cell research to share their recent advances in the field, as well as to train new junior members.

Read more

Diagnosis in hematological diseases: morphology and flow cytometry

This SWG is active in disseminating knowledge on advances in the diagnosis and follow-up by morphology and multiparameter flow-cytometry of malignant and non-malignant hematological diseases. These include morphology, digital morphology, and flow-cytometry (mass, imaging, and spectral flow cytometry included).

Read more

EHA-SWG Transfusion Teaser Meeting

On March 29 the 'teaser' meeting “Transfusion medicine: a short journey around Europe” in which key opinion leaders  discussed shaping the EHA-SWG roadmap in the next 5-10 years took place virtually.

Read more

Introducing YoungEHA: you don’t have to grow old to make a difference

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee. Hearing exciting new research, attending lectures by leaders in the field, and networking are some of the obvious things that are happening during the annual EHA congress.

Read more

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more